Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection
Abstract
Hepatitis C virus (HCV) infection frequently progresses to chronicity rather than spontaneous clearance, resulting in severe liver diseases including cirrhosis and hepatocellular carcinoma. The molecular mechanisms governing infection outcomes remain poorly understood. We identified Peptide A, a highly conserved epitope (residues 442 to 451) within HCV glycoprotein E2, and demonstrated that differential antibody binding patterns to this region correlate with distinct infection outcomes. This immunogenic, nonneutralizing epitope localizes to a structurally exposed region that shares residue 442 as a boundary with the previously characterized Epitope II (residues 430 to 442) and is positioned adjacent to variable region 2 (VR2, residues 460 to 485). Antibodies requiring both F442 and F447 residues within Peptide A for binding emerged early following infection and demonstrated strong correlation with chronic HCV progression. In contrast, antibodies binding exclusively to F447 were associated with spontaneous viral clearance and consistently co-occurred with Epitope II antibodies during later phases of infection. By establishing the relationship between these distinct antibody binding patterns and divergent infection outcomes, our findings elucidate potential HCV immune evasion mechanisms and may facilitate the development of predictive tools for determining chronic versus clearance outcomes early in infection, as well as inform rational vaccine design strategies.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Yong He
Department of Pathogen Biology, School of Basic Medical Sciences, Anhui Medical University
Lilin Zhong
Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Anthony Ruvindi DeSilva
Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Kam Sang Kwok
Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Lu Deng
Department of Animal Nutrition and Environmental Hygiene, College of Animal Science and Technology, Northwest A&F University
Maria Luisa Virata
Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Hailing Yan
Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Dorothy Scott
Division of Plasma Derivatives, Office of Plasma Protein Therapeutics, Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Marian Major
Harvey J. Alter
Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health
Pei Zhang
Department of Neurobiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology